Research Officer - Cancer Biology & Molecular Cell Biology
The University of Queensland Diamantina Institute
The University of Queensland Diamantina Institute (UQDI) was established in 2007 and forms a major research centre within the Faculty of Medicine. The aim of the Institute is to develop a better understanding of the molecular and cellular basis of disease, and to translate that understanding into practical outcomes for patients. Based at the Translational Research Institute (TRI) at the Princess Alexandra Hospital teaching campus in Brisbane, UQDI has more than 300 researchers, clinical academics and students who work closely with hospital clinicians in the areas of cancer, immunology, genomics and other areas of translational medicine. UQDI has particular research strengths in skin cancers, blood cancers and autoimmunity.
UQDI has a mission of translating discoveries into better treatments and has a strong record of achievement, most notably in the development of cancer therapies: research at UQDI by Professor Ian Frazer AC FRS led to the development of the cervical cancer vaccine Gardasil. UQDI is the largest partner in the TRI, which is an extremely well-equipped translational biomedical research institute, with outstanding laboratories and core facilities for imaging, microscopy, flow-cytometry and in vivo models of disease. Its close affiliation with clinical units at Princess Alexandra Hospital provides UQDI with a significant strategic advantage in near-patient, translational research.
UQDI is part of The University of Queensland, one of the top Australasian universities, and internationally is ranked in the top 100 universities in all major independent rankings. UQDI academics are part of a vibrant and highly successful academic institution optimising their chances of research success. Details of the research interests of academic staff maybe accessed on the Institute’s web site at at http://www.di.uq.edu.au/research.
Based at the Translational Research Institute (TRI) at the Princess Alexandra Hospital teaching campus in Brisbane, the Institute has more than 250 researchers and students who work closely with clinicians in the areas of cancer, immunology and genomic medicine. As the largest partner in TRI, UQDI has build and continues to expand major programs in Cancer, Immunology and Genomic Medicine research, with a particular focus on research aimed at development of new treatments. Details of the research interests of academic staff may be accessed on the Institute's web site at http://www.di.uq.edu.au/research
The successful appointee will conduct research in the field of cancer biology and molecular cell biology. You will conduct experiments to predict the cancer cell response to chemotherapy and analyse the genetic characteristics of primary tumor, metastasis, and circulating tumor cells. As well as data analysis and documentation, the position involves supervision of Honours and Research Higher Degree students, publication and presentation of work. As part of a team, the appointee will collaborate and interact with pharmacologist, clinicians and statisticians/bioinformaticians utilising a number of core technologies including single cell sequencing and transcriptomics, flow cytometry and fluorescence microscopy.
Applicants should possess a PhD in cancer biology or molecular cell biology. You should have experience in cell biology/cancer biology techniques, microscopy imagine and conducting animal experiments. You will have contributed to research through publication of scholarly papers in the international literature and, presentation of scientific work at international meetings, as well as demonstrated experience in attractingfunding. You will also have the ability to work collaboratively with colleagues.
The University of Queensland values diversity and inclusion. Applications are particularly encouraged from Aboriginal and Torres Strait Islander peoples. For further information please contact our Australian Indigenous Employment Coordinator at: email@example.com Applications are also encouraged from women. This role is a full-time position; however flexible working arrangements may be negotiated.
This is a part-time , fixed term appointment at Academic level A. The remuneration package will be in the range $48, 927 – 52,521 (part time equivalent) p.a., plus employer superannuation contributions of up to 17% (total package will be in the range $57245 - $61,449 (part time equivalent) p.a.).
To discuss this role please contact Dr Tina Liang on +61 7 3443 7487 or firstname.lastname@example.org
To submit an application for this role, use the Apply button below. All applicants must supply the following documents: Cover letter, Resume and Selection Criteria responses.
For information on completing the application process click here.
More searches like this
- Business and Finance Academic (e.g. 'Lecturer') £30,000 - £39,999 jobs in Australia
- Science Academic (e.g. 'Lecturer') £30,000 - £39,999 jobs in Australia
- Computer Science and IT Academic (e.g. 'Lecturer') £30,000 - £39,999 jobs in Australia
- Life Sciences Academic (e.g. 'Lecturer') £30,000 - £39,999 jobs in Australia
- Cell and Molecular Biology Academic (e.g. 'Lecturer') £30,000 - £39,999 jobs in Australia